Harbour Investments Inc. Buys 20,136 Shares of Pfizer Inc. $PFE

Harbour Investments Inc. lifted its stake in shares of Pfizer Inc. (NYSE:PFE) by 25.9% in the fourth quarter, HoldingsChannel.com reports. The fund owned 97,829 shares of the biopharmaceutical company’s stock after acquiring an additional 20,136 shares during the quarter. Harbour Investments Inc.’s holdings in Pfizer were worth $2,436,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the stock. Brighton Jones LLC increased its position in shares of Pfizer by 1,282.4% in the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock valued at $17,677,000 after acquiring an additional 618,117 shares during the period. Revolve Wealth Partners LLC increased its position in shares of Pfizer by 12.5% during the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after buying an additional 2,087 shares during the period. United Bank increased its position in shares of Pfizer by 12.4% during the second quarter. United Bank now owns 58,087 shares of the biopharmaceutical company’s stock valued at $1,408,000 after buying an additional 6,415 shares during the period. Sei Investments Co. increased its position in shares of Pfizer by 31.5% during the second quarter. Sei Investments Co. now owns 2,635,691 shares of the biopharmaceutical company’s stock valued at $63,889,000 after buying an additional 631,523 shares during the period. Finally, HUB Investment Partners LLC increased its position in shares of Pfizer by 45.3% during the second quarter. HUB Investment Partners LLC now owns 102,327 shares of the biopharmaceutical company’s stock valued at $2,480,000 after buying an additional 31,896 shares during the period. 68.36% of the stock is owned by institutional investors.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer announced new late-stage trial activity for its infant pneumococcal vaccine and obesity drug berobenatide, reinforcing that the company is pushing to build future growth drivers beyond its aging portfolio. Pfizer’s Next-Gen Infant Pneumococcal Vaccine Trial: What Investors Should Watch Now
• Positive Sentiment: BofA Securities raised its price target on Pfizer to $27 from $26 after strong first-quarter results and improved 2026 revenue/EPS estimates, signaling continued analyst confidence in the stock’s valuation. BofA Raises Price Target on Pfizer (PFE) Following Strong Q1 Results
• Positive Sentiment: Pfizer is also highlighting its obesity push with a new Phase 3 trial, which could add another major opportunity if results are favorable. Pfizer Steps Up Obesity Push With New Phase 3 Berobenatide Trial
• Neutral Sentiment: Recent commentary says Pfizer is leaning on new launches, Seagen assets, and pipeline progress to offset looming loss-of-exclusivity pressure, but the patent cliff through 2030 remains a major overhang for investors. Pfizer Bets on New & Acquired Drugs to Offset Its LOE Pressure?
• Negative Sentiment: Broader industry coverage on the Eliquis patent cliff underscores the kind of revenue loss Pfizer and peers can face when exclusivity ends, keeping attention on the company’s future replacement pipeline. Thinning revenues: inside the $14bn Eliquis patent cliff

Pfizer Stock Up 1.5%

Shares of NYSE:PFE opened at $26.24 on Thursday. The stock has a fifty day simple moving average of $26.82 and a two-hundred day simple moving average of $26.27. The stock has a market capitalization of $149.55 billion, a price-to-earnings ratio of 20.03 and a beta of 0.35. Pfizer Inc. has a 12-month low of $23.06 and a 12-month high of $28.75. The company has a current ratio of 1.25, a quick ratio of 0.94 and a debt-to-equity ratio of 0.67.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. The business had revenue of $14.45 billion during the quarter, compared to analysts’ expectations of $13.84 billion. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The firm’s quarterly revenue was up 5.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.92 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, research analysts anticipate that Pfizer Inc. will post 2.99 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, June 12th. Stockholders of record on Friday, May 8th will be issued a dividend of $0.43 per share. The ex-dividend date is Friday, May 8th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.6%. Pfizer’s dividend payout ratio is presently 131.30%.

Wall Street Analyst Weigh In

PFE has been the topic of several research analyst reports. Cantor Fitzgerald reiterated a “neutral” rating and set a $27.00 price target on shares of Pfizer in a research report on Wednesday, February 4th. Zacks Research upgraded shares of Pfizer from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 24th. Weiss Ratings upgraded shares of Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, May 6th. Daiwa Securities Group cut shares of Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 price target on the stock. in a research report on Thursday, February 12th. Finally, CICC Research initiated coverage on shares of Pfizer in a research report on Thursday, April 16th. They set an “outperform” rating and a $33.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, twelve have given a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $28.61.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.